Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?
Approval Was the First Hurdle, Not the Last Revolution Medicines, Inc. (NASDAQ:RVMD) is no longer valuing a theoretical pancreatic cancer drug.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 770,000 | $992,661 | -40% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | $34,999,974.00 | 760,869 | 2024-12-05 | Filing | |
| $46.00 | 543,478 | $24,999,988.00 | 2,096,612 | 2024-12-05 | Filing | |
| $20.85 | 6,200 | $129,270.00 | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | $1,916,334.00 | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | $6,999,982.00 | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $204.72 | 301 | $61,621.44 | 52,559 | 2026-09-29 | Filing | |
| $203.91 | 1,199 | $244,484.97 | 52,860 | 2026-09-29 | Filing | |
| $202.81 | 1,000 | $202,812.70 | 54,059 | 2026-09-29 | Filing | |
| $201.72 | 1,609 | $324,573.76 | 55,059 | 2026-09-29 | Filing | |
| $200.82 | 2,200 | $441,801.36 | 56,668 | 2026-09-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,181,185 | $447,710,033 | 0.43% | |
| 2. | 48,743,000 | $62,789,138 | 2.28% | |
| 3. | 274,561 | $56,356,391 | 1.3% | |
| 4. | 100,472 | $20,622,882 | 0.06% | |
| 5. | 94,803 | $19,459,264 | 2.49% |
News See All
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Revolution Medicines' (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here.
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
Reuters reported that the FDA approved Revolution Medicines, Inc.
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review.
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP.
Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug
Shares in oncology drugs group Revolution Medicines ($RVMD) were healthier again today after a leading analyst said its new pancreatic cancer drug ...
Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval
Shares in oncology drugs group Revolution Medicines ($RVMD) were higher today after the U.S. Food and Drug Administration approved its treatment fo...
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal.
Hedge Fund Resource Center